Anaesthesiology Intensive Therapy, 2010,XLII,3; 144-149

Antimicrobial therapy in severe infections with multidrug-resistant Gram-negative bacteria

*Wiesława Duszyńska


I Department of Anaesthesiology and Intensive Therapy, Medical University of Wrocław

  • Table 1. Carbapenems – similarities and differences
  • Table 2. Shortened guidelines for antibiotic therapy according to (3)

Multidrug-resistant Gram-negative bacteria pose a serious and rapidly emerging threat to patients in healthcare settings, and are especially prevalent and problematic in intensive therapy units. Recently, the emergence of pandrug-resistance in Gram-negative bacteria poses additional concerns. This review examines the clinical impact and epidemiology of multidrug-resistant Gram-negative bacteria as a cause of increased morbidity and mortality among ITU patients. Beta-lactamases, cephalosporinases and carbapenemases play the most important role in resistance to antibiotics.

Despite the tendency to increased resistance, carbapenems administered by continuous infusion remain the most effective drugs in severe sepsis. Drug concentration monitoring, albeit rarely used in practice, is necessary to  ensure an effective therapeutic effect.

Infections with Gram-negative bacteria generate a serious therapeutic problem in ITU patients because of a high percentage of multidrug-resistant bacterial strains [1]. Increasingly high resistance to antibiotics of at least three antibiotic groups has narrowed the therapeutic options. In many cases, due to this multiple-drug resistance (MDR) observed in Gram-negative bacteria, the treatment is limited to carbapenems and polymixins E or B. A particularly dangerous phenomenon is the emergence of pan-drug resistance in Gram-negative bacteria. Although the literature offers numerous guidelines and recommendations for the therapy of severe infections [2, 3, 4, 5], the choice of an appropriate antibiotic for empiric therapy should be additionally supported by the epidemiological analysis of a given ward in nosocomial infections and of the region or country in cases of out-of-hospital infections. Depending on the mechanism of resistance, fluoroguinolones (particularly ciprofloxacin), aminoglycosides (particularly amikacin), piperacillin with tazobactam, and tigecycline might also prove effective. In cases of infections with multidrug-resistant non-fermenting bacteria, the combined therapy using colistine with rifampicin [6], colistin with imipenem or meropenem should be considered. The clinical cases published indicate the effectiveness of therapy with colistine combined with meropenem, ofloxacine and gentamicin [7], and colistine combined with meropenem and tigecycline [8]. Moreover, in infections of the lower respiratory tract, antibiotics can be administered by inhalation [9, 10].

MDR has become a global public health problem. Amongst six most dangerous pathogens with rapidly increasing antibiotic resistance, called “alert-pathogens” and defined in 2004 by the Infectious Diseases Society of America (IDSA) as ESCAPE, four types of Gram-negative bacteria were listed, i.e. Klebsiella, Enterobacter, Pseudomonas aeruginosa and Acinetobacter Baumanni [11].

The major resistance mechanisms of Gram-negative bacteria are associated with:

  • extended-spectrum-beta-lactamases (ESBLs), which occur most commonly in Klebsiella pneumoniae, Escherichia coli as well as Proteus spp, Serratia spp, Enterobacter spp, Pseudomonas spp, and Salmonella spp,
  • AmpC cephalosporinases occurring predominantly in Enterobacter spp, Citrobacter spp, Serratia spp,
  • carbapenemases found mainly in Enterobacter cloacae, Serratia marcescens, Citrobacter freundii, Klebsiella pneumoniae, Proteus spp as well as Pseudomonas aeruginosa, Acinetobacter and Alcaligenes [12, 13].

According to the Ambler classification, carbapenemases belong to molecular class A (penicilinases), class D (oxacilinases) – serine enzymes or class B (metallo-beta-lactamases) requiring a bivalent metal (most often zinc) ion as a cofactor of enzymatic reactions [13].

In clinical practice, the occurrence of the mechanisms listed above provides information about therapeutic possibilities and their potential clinical efficacy although this efficacy is affected by many other factors depending not only on the pathogen but also on the clinical status of a patient and the kind of an antibiotic.

In ESBL strains, the drugs of choice are carbapenems, yet piperacillin with tazobactam (Pip/Taz), aminoglycosides, and fluoroquinolones may also be effective. These strains are always resistant to penicillins, cephalosporins and monobactams. Pip/Taz, aminoglycosides and fluoroquinolones should be used only for target therapy with monitoring of MIC and, if possible, of serum concentrations and pharmacokinetic and inflammatory parameters as the markers of clinical efficacy. Piperacillin with tazobactam should not be used for empiric therapy of severe pneumonias and abdominal infections when the pathogens are ESBL-producing Gram-negative bacteria due to the inoculum effect. However, this combination can be used for urinary infections. The percentage of strains producing ESBLs amongst  Enterobacteriaceae strains in Polish hospitals in the Beta-P1 Study Group was 11.1% [14].

In cases of chromosomal AmpC cephalosporinases, carbapenems and cefepime are found clinically effective. The latter will not be useful if the strain with AmpC cephalosporinases produces also ESBLs [15]. The majority of carbapenemases is active towards not only carbapenems but also penicillins, cephalosporins, or monobactams.

Metallo-beta-lactamases do not undergo inactivation under the influence of beta-lactamase inhibitors (tazobactam, sulbactam, clavulanic acid). The substrate range of metallo-enzymes does not include monobactams; hence, almost all metallo-beta-lactamases induce the resistance to all beta-lactam antibiotics, except for aztreonam. Serine carbapenemases of class A and D are, though to a various extent, susceptible to the inhibitory activity of clavulanic acid, tazobactam and sulbactam; therefore, combinations of beta-lactam antibiotic with beta-lactamase inhibitor may be used [15, 17]. It should be remembered, however, that Gram-negative bacteria are likely to exhibit several independent mechanisms of resistance.

Klebsiella pneumoniae carbapenemases (KPCs) hydrolyze all carbapenems and all the remaining beta-lactam antibiotics. They occur most commonly in Klebsiella pneumoniae, oxytoca as well as Enterobacteriacae and Pseudomonas (aeruginosa, putida). Strains of Klebsiella pneumoniae KPC+ are usually sensitive only to colistin, tigecycline, gentamicin, sometimes to amikacin [17]. The clinical efficacy of the drugs listed was not confirmed by clinical trials. The guidelines for the family of KPC-producing Enterobacteriaceae are available on the Web site of the National Reference Centre for Drug Susceptibility of Microorganisms – www.korld.edu.pl.

The resistance of bacteria to carbapenems is likely to result not only from the production of enzymes inactivating beta-lactamases but also decreased permeability of the external membrane, changes in penicillin-binding proteins, and active removal of the an antibiotic from the cell [15].

Despite alarmingly increasing resistance of Gram-negative bacteria, carbapenems are still a relevant therapeutic option for patients with severe sepsis and septic shock. Three carbapenems of group II (imipenem, meropenem, doripenem) and one of group I (ertapenem) registered currently in Poland have a wide spectrum of action against Gram-negative bacteria (except for Stenotrophomonas maltophilia, Burkholderia cepacia, Chrysobacterium meningosepticum (and Pseudomonas aeruginosa in the case of ertapenem) and Gram-positive bacteria (except for Enterococus faecium, MRSA, MRSE, Corynebacterium jejkeium), including anaerobes. Their different references, pharmacokinetic parameters and dosages are of interest [18, 19, 20] and are listed in Table 1.

Prior to antibiotic therapy, the parameters determining the highest probability of a beneficial clinical effect ought to be considered and the toxic action minimized; moreover, the therapy should be relatively short (pharmacoeconomic effect), and risk of increasing resistance minimized [21, 22]. The pharmacokinetic parameters of an antibiotic are also relevant, i.e. Vd, T1/2, the type of metabolism, excretion pathway, penetration to the infection site, affinity of an antibiotic to water or fat. Some antibiotics/chemotherapeutics require the correction of doses in renal or hepatic failure, obesity, and renal replacement therapy. In the therapy with aminoglycosides and vancomycin, monitoring of their blood concentrations is needed because of high toxicity if overdosed.

The pharmacokinetic-pharmacodynamic (PK/PD) modelling is the management of infections aimed at increased efficacy and safety as well as reduced treatment-related costs. The changes in physiological and biochemical parameters in patients with severe sepsis and septic shock, such as reduced arterial blood pressure and cardiac output, increased permeability of capillaries, features of venostasis, acid-base imbalance, hypo- or hypervolaemia, decreased protein/albumin levels, features of renal and/or hepatic failure, affect the pharmacokinetic parameters of antibiotics [22, 23, 24].

Due to the changes in pharmacokinetic parameters of antibiotics (e.g. distribution volume, T1/2, clearance as well as metabolism and excretion) in patients with severe sepsis or septic shock, the action of the drug inside the body cannot be accurately anticipated. Monitoring of drug concentrations, particularly in patients undergoing intensive therapy, seems to be fully grounded. 

The principles of PK/PD modelling, which are based on indices attributed to various antibiotics or their groups, provide higher probability of the clinical effect expected. The expected probability of bacteriostatic or bactericidal target attainment (%) for various antibiotics and their different doses against various pathogens in a given population was called the cumulative fraction of response (CFR). The PK/PD targets (the percentage of time between successive doses of the antibiotic when the concentration of free fraction exceeds MIC) determined for achieving a bacteriostatic / bactericidal effect are 30/50% for penicillins, 40/70% for cephalosporins, 20/40% for carbapenems, respectively [23, 25, 26, 27]. The clinical studies demonstrate that beta-lactam antibiotics reach their highest expected clinical efficacy when the stationary concentration of drug free fraction (Cssff) maintains for over 50-70% of time between successive doses, exceeding the MIC for the pathogen four times. The exceptions are carbapenems, which is associated with slight post-antibiotic effects against Gram-negative bacteria [28, 29, 39]. Infections caused by Gram-negative bacteria require higher values of PD index (optimal % T>MIC should fluctuate around 100%) compared to those induced by Gram-positive bacteria. Aminoglycoside antibiotics, quinolons, macrolides, tetracyclines, glycopeptides, glycyclines, and echinocandins have different pharmacodynamic indices and the anticipated therapeutic success depends on Cmax/MIC and/or AUC 24/MIC [29, 30, 33, 43, 46].

According to the PK/PD principles, to optimize beta-lactam antibiotic treatment, prolonged or continuous venous infusions should be used taking into account their time of pharmacological stability (in the solution administered) at room temperature.

The benefits of continuous or prolonged intravenous infusions of antibiotics include better clinical efficacy and eradication, better action against multi-resistant strains, reduced  resistance, lower incidence of side effects, shorter therapy, and lower costs [24, 28]. The pharmacokinetic consequences of continuous or prolonged infusions are quick saturation with the drug proper dose, maintenance of the drug concentration - minimal and maximal stationary concentration – throughout the administration period, prolonged mean time the drug stays in the body, quick clinical effects thanks to better availability of the drug.

Improper empiric therapy or wrong timing of its implementation decreases the chances for survival [31, 32]. Numerous studies concerning antibiotic therapy search for the proper strategy of their dosing and optimal clinical doses under given circumstances [44, 45, 46, 47, 48, 49, 50]. The use of continuous and prolonged infusions requires further clinical studies to become the evidence-based management. According to the guidelines for management in severe sepsis and septic shock, the drug concentration should be determined, as an element of PK/PD monitoring. Table 2, presenting the shortened principles of antibiotic therapy, contains some comments regarding the management in question [3]. 

With increased resistance of bacterial strains to the antibiotics used, severe infections cannot be properly treated without the cooperation of clinicians, microbiologists and clinical pharmacologists.

..............................................................................................................................................................

REFERENCES

1.    Howard DH: The global impact of drug resistance. Clin Infect Dis 2003; 36: 4-10.

2.    Niederman MS, Craven DE, Bonten MJ, Chastre J,  Craig WA, Fagon J, Holl J, Jacoby GA, Kollef MH, Luna LA, Mandell A, Torres RG, Wunderink A: American Thoracic Society and Infections Dieseases Society of America (ATS/IDSA) guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.

3.    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent J-L: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock 2008. Crit Care Med 2008; 36: 296-327.

4.    Mandell LA, Wunderink RG, Anzueto A, Bartlett A,Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torre A, Whitney CG: IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: (Suppl. 2): S27-S72.

5.    Solomkin JS, Mazurski JE, Bradley JS, Rodvolt KA,Goldstein EJC, Baron EJ, O’Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach Sh, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the SIS and IDSA. 2010 Clin Infect Dis 2010; 50: 133-164.

6.    Rokosz A, Sawicka-Grzelak A, Łuczak M: Wrażliwość in vitro MBL-dodatnich klinicznych szczepów Gram(-) pałeczek na leki przeciwbakteryjne. Zakażenia 2006; 6: 28-33.

7.    Falagas M E, Bliziotis IA, Kasiakou S K,Samonis G, Athanassopoulou P, Michalopoulos A: Outcame of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5: 24. 

8.    Taccone FS, Rodrigues-Villalobos H, De Backer D: Successful treatment of septic shock due to pan-resistant Acinetobacter baumanii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-260.

9.    Robinson BR, Athota KP, Branson RD: Inhalational therapies for the ICU. Curr Opin Crit Care 2009; 15: 1-9.

10.    Michalopoulos A, Papadakis E: Inhaled anti-infective agents: emphasis colistin. Infection 2010; 38: 81-88.

11.    Boucher HW, Talbod GH, Bradley JS,Edwards JE Jr, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs, no ESCAPE. Clin Infect Dis 2009; 1: 1-12.

12.    Ziółkowski G, Ziółkowska B: Wpływ antybiotykoterapii na wielooporność patogenów bakteryjnych. Sepsis 2009; 2: 155-164.

13.    Romaszczyn D: Pałeczki Gram(-) w zakażeniach szpitalnych. Zakażenia 2005; 5: 28-30.

14.    Empel J, Baraniak A, Literacka, Mrówka A, Fiett J, Sadowy E, Hryniewicz W, Gniadkowski M: Beta-P1 study Group: Molecular survey of beta lactamases conferring resistance to newer beta lactams in Enterobacteriaceae isolates from polish hospitals. Antimicrob Agents Chemother 2008; 52: 2449-2454.

15.    Laudy AE: Karbapenemazy – enzymy mogące hydrolizować szerokie spektrum beta-lactamów. Zakażenia 2003; 4: 32-38.

16.    Drzewiecki A: Cefalosporyny III i IV generacji – miejsce w lecznictwie. Zakażenia 2009; 9: 29-33.

17.    Hryniewicz W, Gniatkowski M: Oporność na karbapenemy u pałeczek Enterobacteriacae w wyniku wytwarzania karbapenemaz – wytyczne postępowania. Med Prakt 2009; 225: 137-140.

18.    Zhanel GG,Wiebe R, Dilay L, Thomson K, Rubinstein E,Hoban DJ, Noreddin AM, Karlowsky J: Comparative review of the carbapenems. Drugs 2007;67:1027-1052.

19.    Rahal JJ: The role of carbapenems in initial therapy for serious Gram negative infections. Crit Care 2008; 12 (Suppl. 4): S5.

20.    Drzewiecki A: Karbapenemy w zakażeniach szpitalnych spowodowanych przez wielooporne bakterie. Zakażenia 2009; 2: 34-39.

21.    Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y: Potency of carbapenems for prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of new carbapenem doripenem. J Antibiot 2006; 59: 220-228.

22.    Roberts JA, Kruger P, Paterson DL, Lipman J: Antibiotic resistance. What’s dosing got to do with it? Crit Care Med 2008; 36: 2433-2440.

23.    Lodise TP, Lomaestro BM, Drusano GL: Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics. Pharmacotherapy 2006; 26: 1320-1332.

24.    Roberts JA, Lipman J: Antimicrobial dosing in intensive care :pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-773.

25.    Novelli A, Adembri C, Livi P, Fallani S, Mazzeri T: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44: 539-549.

26.    Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patients. Crit Care Med 2009; 37: 840-851.

27.    Tze-Peng Lim, Garey KW, Tam VH: Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimalization strategies. Curr Infect Dis Rep 2008; 10: 9-13.

28.    Reese AM, Frei CR, Burgess DS: Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepim against extended-spectrum beta-lactamase-producing organisms. Int J Antimicrob Agents 2005; 26: 114-119.

29.    Scalione F: Can PK/PD be used in everyday clinical practice?  J Antimicrob Agents 2002; 19: 349-353.

30.    Smuszkiewicz P, Szałek E, Toczak H, Trojanowska I, Błaszczyk M: Farmakokinetyczno-farmakodynamiczne zasady stosowania antybiotyków u chorych leczonych z powodu sepsy. Anest Inten Terap 2007; 39: 166-174.

31.    Kumar A, Roberts D, Wood KE, Light B, Parill JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Tailberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.

32.    Kumar A, Ellis P,  Arabi Y, Roberts D, Bruce L, Parillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters Ch, Ahsan M, Chateau D: Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.

33.    Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent J-L, Jacoba F: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.

34.    Rafati MR, Rouni MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholamic K, Fazeli MR: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006; 28: 122-127.

35.    Kasiakou SK, Sermaides GJ, Soteriades ES, Falagos ME: Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005; 5: 581-589.

36.    Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP: The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion. Intensive Crit Care Nurs 2005; 21: 87-93.

37.    Kim A, Sutherland ChA, Kuti JL, Nicolau DP: Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy 2007; 27: 1490-1497.

38.    Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis-Bolus versus continuous administration? Crit Care Med 2009; 37: 926-933.

39.    Lorente L, Lisset L, Martin MM, Jimenez A, Mora MM: Meropenem by continuous versus intermittent infusion in ventilator –associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40: 219-224.

40.    Buck Ch, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD: Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005; 25: 62-67.

41.    Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R: Clinical efficacy and pharmacoeconomics of a continous-infuson piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22: 471-483.

42.    Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-163.

43.    Martin J H ,Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GR: Therapeutic monitoring of vancomycin in adult patients: consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Clin Biochem Rev 2010; 31: 21-24.

44.    Pai MP, Bearden DT: Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-1091.

45.    Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-1336.

46.    Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM: Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63: 1050-1057.

47.    Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J: Is continuous infusion ceftriaxon better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59: 285-291.

48.    Roberts JA, Paratz JD, Lipman J: Continuous infusion of beta-lactams in the intensive care units –best way to hit the target? Crit Care Med 2008; 36: 1663-1664.

49.    Roberts JA, Webb S, Paterson D, Ho HK, Lipman J.A: Systematic review on clinical benefits of continuous administration of beta-lactams. Crit Care Med 2009; 37: 2071-2078.

50.    McKinon PS, Paladino JA Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepim and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-351.

..............................................................................................................................................................

Address:

*Wiesława Duszyńska

Katedra i I Klinika Anestezjologii i Intensywnej Terapii
Akademii Medycznej we Wrocławiu
Akademicki Szpital Kliniczny
ul. Borowska 213, 50-556 Wrocław
w.duszynska@onet.eu

Received: 25.04.2010
Accepted: 27.07.2010